Ciprofloxacin Bioavailability is Enhanced by Oral Co-Administration with Phenazopyridine: A Pharmacokinetic Study in a Mexican Population

Authors: Marcelín-Jiménez, Gabriel1; Ángeles, Alionka P.1; Martínez-Rossier, Luis1; S, Adolfo Fernández1

Source: Clinical Drug Investigation, Volume 26, Number 6, 2006 , pp. 323-328(6)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background and objective: In Mexico, urinary tract infections (UTIs) constitute the second most frequent type of infections treated at primary-care clinics. Ciprofloxacin has played a major role in the treatment of UTIs because it has a broad spectrum of antibacterial activity. In addition to antimicrobial agents, phenazopyridine has been used to alleviate symptoms that occur during episodes of UTI. Thus, the present study was designed to compare the pharmacokinetic behaviour of ciprofloxacin administered alone versus ciprofloxacin combined with phenazopyridine.

Patients and methods: Twenty-four healthy male Mexican volunteers participated in this project. The study was carried out with a single oral dose of ciprofloxacin 500mg. The double-blind, crossover, randomised, balanced trial design comprised two treatments, two periods and two sequences. After administration of the study medication, serial blood samples were collected for a period of 12 hours. The harvested plasma was analysed for ciprofloxacin by high-performance liquid chromatography. The area under the concentration-time curve to last measurable concentration (AUCt), area under the concentration-time curve extrapolated to infinity (AUC), peak plasma concentration (Cmax), time to reach Cmax (tmax), mean residence time (MRT), elimination constant (ke) and elimination half-life (t½) were determined from plasma concentrations of both treatments and considered as primary variables for statistical analysis.

Results: While there were no differences between the two treatments in terms of Cmax and ke, AUCt and AUC were 35% and 29% higher, respectively, in the combined treatment arm. Moreover, a significant delay in tmax (from 1 to 1.5 hours) and a statistical increase of 29% in MRT were also observed with phenazopyridine co-administration.

Conclusion: Oral co-administration of phenazopyridine increases ciprofloxacin bioavailability with regard to the amount absorbed (AUC) and permanence in the body (MRT), which could be useful during treatment.

Keywords: Bioavailability; Ciprofloxacin; Fluoroquinolones; Non opioid analgesics; Phenazopyridine; Urinary tract infections

Document Type: Research article

Affiliations: 1: Servicio de Investigación de Farmacología Clínica, Hospital General de México, Mexico City, Mexico

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$62.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A